 ADC Therapeutics SA NYSE: ADCT has scored an FDA approval for Zynlonta, formerly known as loncastuximab tesirine, as a solo treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL after two prior lines of therapy. Following a priority review in November with a review date of May 21, Zylontas accelerated nod comes a month ahead of schedule. 